Related references
Note: Only part of the references are listed.Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry
Gherardo Tapete et al.
INFLAMMATORY BOWEL DISEASES (2022)
Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
Ferdinando D'Amico et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients
Antonio Tursi et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
Linda Cingolani et al.
SCIENTIFIC REPORTS (2021)
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis
J. Hercogova et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre
Martin Lukas et al.
JOURNAL OF CROHNS & COLITIS (2020)
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study
Davide Giuseppe Ribaldone et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2020)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Biosimilars of adalimumab: the upcoming challenge in IBD
Gionata Fiorino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
Remo Panaccione et al.
JOURNAL OF CROHNS & COLITIS (2018)
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Vandana Midha et al.
INTESTINAL RESEARCH (2018)
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2017)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials
A. Cholapranee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
Jean-Frederic Colombel et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
The economic burden of TNF alpha inhibitors and other biologic treatments in Norway
Jan Norum et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Predicting the Crohn's disease activity index from the Harvey-Bradshaw index
WR Best
INFLAMMATORY BOWEL DISEASES (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)